HealthcareServices

Meibomian Gland Dysfunction Market 2026–2030: Forecasting Business Opportunities Ahead

March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the meibomian gland dysfunction market from 2026–2035 with trusted insights from The Business Research Company

How is the Meibomian Gland Dysfunction Market size predicted to change over the forecast window of 2026–2035?

The meibomian gland dysfunction market size has experienced robust growth in recent years. It is projected to expand from $4.42 billion in 2025 to $4.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. The expansion observed historically stems from factors such as the increasing incidence of dry eye disease, elevated screen time exposure, the growth of the aging population, wider clinical recognition of MGD, and the availability of basic treatment options.

The meibomian gland dysfunction market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $6.12 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This projected increase during the forecast period is driven by several factors, including the rising acceptance of device-assisted treatments, augmented investments in eye care, heightened public understanding of persistent eye ailments, wider availability of at-home treatment devices, and a greater emphasis on customized eye care solutions. Key developments anticipated during this period encompass the broader implementation of sophisticated diagnostic instruments, an uptick in the utilization of device-based therapeutic options, a stronger inclination towards combined treatment strategies, the proliferation of home-based management alternatives, and an intensified commitment to detecting diseases early.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24602&type=smp

Which Drivers Are Contributing To The Expansion Of The Meibomian Gland Dysfunction Market?

The increasing incidence of eye disease is anticipated to drive the expansion of the meibomian gland dysfunction (MGD) market in the coming years. Eye disease refers to any condition or disorder that impacts the eye or visual system, thereby hindering its structure, function, or overall health. The rising occurrence of eye disease is linked to greater screen time and digital eye strain, which result in symptoms such as dryness, blurred vision, and long-term retinal damage from prolonged blue light exposure. Meibomian gland dysfunction contributes to eye disease by disrupting the stability of the tear film, leading to inflammation, dryness, and a heightened risk of ocular surface disorders. For example, in February 2025, according to the National Institutes of Health (NIH), a US-based government agency, the global prevalence of myopia is projected to increase to 36.59% by 2040 and 39.80% by 2050, with the total number of cases expected to exceed 740 million by 2050. Therefore, the growing number of eye disease cases is propelling the growth of the meibomian gland dysfunction (MGD) market.

What Segment Categories Are Covered In The Meibomian Gland Dysfunction Market?

The meibomian gland dysfunction market covered in this report is segmented –

1) By Treatment Type: Medication, Surgery, Lifestyle Modifications

2) By Dysfunction Type: Obstructive Meibomian Gland Dysfunction, Evaporative Meibomian Gland Dysfunction, Mixed Meibomian Gland Dysfunction

3) By Disease Severity: Mild Meibomian Gland Dysfunction, Moderate Meibomian Gland Dysfunction, Severe Meibomian Gland Dysfunction

4) By Distribution channel: Hospitals And Clinics, Pharmacies, Online Retailers

5) By End-User: Hospitals, Ophthalmology Clinics, Home Care Settings

Subsegments:

1) By Medication: Topical Antibiotics, Topical Steroids, Lubricating Eye Drops, Topical Cyclosporine, Omega-3 Supplements

2) By Surgery: Meibomian Gland Probing, Intense Pulsed Light (IPL) Therapy, Thermal Pulsation Treatment, BlephEx

3) By Lifestyle Modifications: Warm Compress Therapy, Lid Hygiene, Dietary Adjustments, Blinking Exercises

Which Innovation Trends Are Advancing Developments Within The Meibomian Gland Dysfunction Market?

Leading companies operating in the meibomian gland dysfunction market are concentrating on developing novel treatments, such as prescription eye drop solutions, to diminish tear evaporation and alleviate dry eye symptoms. Prescription eye drop solutions, including anti-inflammatory or antibiotic varieties, help manage meibomian gland dysfunction by reducing inflammation, clearing gland blockages, and improving tear film stability. For instance, in May 2023, Bausch + Lomb Corporation, an eye health company based in Canada, introduced MIEBO (perfluorohexyloctane ophthalmic solution), a groundbreaking prescription eye drop created for treating dry eye disease (DED). As the initial and sole prescription eye drop to directly address tear evaporation, which is the primary cause of DED, MIEBO forms a protective, durable layer over the eye’s surface. Its innovative water-free formulation delivers effective and lasting relief, particularly for patients experiencing dry eye symptoms associated with Meibomian gland dysfunction.

Which Major Firms Are Strengthening Their Position In The Meibomian Gland Dysfunction Market?

Major companies operating in the meibomian gland dysfunction market are Johnson And Johnson, Alcon Inc., Bausch Lomb Corporation, Santen Pharmaceutical, Lumenis Ltd, Topcon Healthcare Solutions Inc, AFT Pharmaceuticals, Sight Sciences Inc, OASIS Medical Inc, OCuSOFT Inc, Novaliq GmbH, Scope Ophthalmics Ltd, Medmont International Pty Ltd, Azura Ophthalmics Ltd, BlephEx LLC, Bruder Healthcare Company, ESW Vision Inc, MiBo Medical Group Inc, Kala Pharmaceuticals Inc, Allergan Eye Care, TearScience Inc, Sun Pharmaceutical Industries Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/meibomian-gland-dysfunction-global-market-report

Which Regions Are Projected To Dominate The Meibomian Gland Dysfunction Market In The Coming Years?

North America was the largest region in the meibomian gland dysfunction market in 2025. The regions covered in the meibomian gland dysfunction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Meibomian Gland Dysfunction Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24602&type=smp

Browse Through More Reports Similar to the Global Meibomian Gland Dysfunction Market 2026, By The Business Research Company

Mastopexy Market Report 2026

https://www.thebusinessresearchcompany.com/report/mastopexy-global-market-report

Drugs For Hormonal Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Combined Pituitary Hormone Deficiencies Market Report 2026

https://www.thebusinessresearchcompany.com/report/combined-pituitary-hormone-deficiencies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795